View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ackermans & van Haaren: Committed partners of progress in a consolidating industry. Arcadis: No small beer. Kinepolis: Two new rented cinemas in Spanish commercial centres. Vonovia: Completing Deutsche Wohnen acquisition

 PRESS RELEASE

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE...

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology co...

Argen X SE: 1 director

A director at Argen X SE sold 924 shares at 495.250EUR and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ING Benelux Conference London: Aalberts, Arcadis, Azelis, Barco, Basic-Fit, Brunel International, DEME Group, Euronext, Fagron, Heijmans, Kinepolis, Lotus Bakeries, Melexis, Ontex, Randstad, Recticel, SBM Offshore, TKH Group, Van Lanschot Kempen Other company stories - OCI: Divestment of Methanol to Methanex for US$2.05bn, Staffing: US August temp volumes marginally better trend; NFP jobs miss

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Wim Lewi
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri

ODDO : Semiconductor sales in July 2024 in line with forecasts, still ...

>Worldwide sales in July 2024 in line with our forecasts +18.7% y-o-y vs +18.5% in June - Worldwide semiconductor sales in July 2024 were published by the WSTS (World Semiconductor Trade Statistics) with the usual one-month lag. In terms of the 3-month moving average, sales were $ 51.3bn, in line with our estimate, i.e. +2.5% on a sequential basis and y-o-y growth of +18.7%, after 18.5% in June.Continued strong growth in memory thanks to prices, a slight...

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri

ODDO : Ventes de semi-conducteurs de juillet 2024 en ligne avec nos at...

>Ventes mondiales de juillet 2024 en ligne avec nos attentes à +18.7% yoy vs +18.5% en juin - Les ventes mondiales de semiconducteurs de mai 2024 ont été publiées par WSTS (World Semiconductor Trade Statistics), avec (comme toujours) un mois de décalage. En donnée lissées (moyenne de 3 mois), elles ressortent à 51,3 Md$, en ligne avec notre prévision, à +2.5% en séquentiel et en croissance annuelle de +18.7%, après 18.5% en juin.Poursuite de la forte cr...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

BE Semiconductor Industries: Cash keeps flowing. KBC: Belgian peer Belfius results. KBC Ancora: FY23/24 in line, discount of -34% too high

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Thibault Leneeuw
  • Wim Hoste
  • Wim Lewi
Quirijn Mulder
  • Quirijn Mulder

Arcadis/Nicely on track for FY26 targets/BUY

With especially strong 2Q24 margins up 170bp YoY, we have adjusted our estimates. Expecting organic growth to accelerate from 2H24 onwards, we foresee double-digit growth of its EBITDA and EBITA from operations in FY24-26F. With Arcadis at an EV/EBIT 2024-26F discount of 18% to its peer group, we believe the valuation continues to be too low. Risks have certainly diminished on the back of well financed and better performing acquired companies but on margins Arcadis still can win and therefore we...

Martijn Den Drijver
  • Martijn Den Drijver

ODDO BHF Small & MIDCAP MORNING NEWS - 08/28/2024

We initiate the coverage of Ypsomed with a target price of CHF 495 and an Outperform rating. As a leading developer and manufacturer of a broad portfolio of injection systems for the self-medication of liquid drugs, Ypsomed will benefit from major trends in the healthcare industry. The company is currently in a transformation process to exit non-core activities and to focus on the fast-growing and highly profitable Delivery Systems business. This is expected to lead on our estimates t...

Martijn Den Drijver
  • Martijn Den Drijver

ODDO BHF Small & MIDCAP MORNING NEWS - 28/08/2024

We initiate the coverage of Ypsomed with a target price of CHF 495 and an Outperform rating. As a leading developer and manufacturer of a broad portfolio of injection systems for the self-medication of liquid drugs, Ypsomed will benefit from major trends in the healthcare industry. The company is currently in a transformation process to exit non-core activities and to focus on the fast-growing and highly profitable Delivery Systems business. This is expected to lead on our estimates t...

Martijn Den Drijver
  • Martijn Den Drijver

Arcadis : Post results note: upping estimates and TP on back of strong...

>Upping organic growth, EBITA and EBITA margin estimates - Both organic growth, EBITA and the EBITA margin were better than expected in Q2 2024 with the latter still not seeing any impact yet from the digitisation/automation program and only a headwind from the GEC program (strong FTE additions and thus opex but without the benefit of increased billability), which will start to have a material impact as of 2025. Due to the acceleration of the backlog growth (from 4.8%...

 PRESS RELEASE

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference. Fireside chat on Wednesday, September 4, 2024 at 1:30 p.m. ET in Boston, MA.Morgan Stanley 22nd Annual Global Healthcare Conference. Fireside chat on Thursday, September 5, 2024 at 4:50 p.m....

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch